Cargando…

Switching to aripiprazole for the treatment of residual mutism resulted in distinct clinical courses in two catatonic schizophrenia cases

OBJECTIVES: The efficacy of a partial agonist for the dopamine D(2) receptor, aripiprazole, for catatonia in schizophrenia has been reported. METHODS: We report distinct clinical courses in challenging aripiprazole to treat residual mutism after severe catatonic symptoms improved. RESULTS: In the fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muneoka, Katsumasa, Kanahara, Nobuhisa, Kimura, Shou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315413/ https://www.ncbi.nlm.nih.gov/pubmed/28255444 http://dx.doi.org/10.1177/2050313X17692936

Ejemplares similares

Treatment of refractory catatonic schizophrenia with low dose aripiprazole
por: Sasaki, Tsuyoshi, et al.
Publicado: (2012)

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
por: Takase, Masayuki, et al.
Publicado: (2015)

Treatment resistant non-catatonic mutism in schizophrenia responding to a combination of continuation electroconvulsive therapy and neuroleptics
por: Grover, Sandeep, et al.
Publicado: (2012)

Rapid Response of Long-Standing, Treatment-Resistant Non-Catatonic Mutism in Paranoid Schizophrenia with Single ECT session
por: Dar, Mansoor Ahmad, et al.
Publicado: (2014)

ECT induced mania in catatonic schizophrenia.
por: Agnihotri, Shruti, et al.
Publicado: (2022)

Wernicke encephalopathy complicating catatonic schizophrenia
por: Rihab, C., et al.
Publicado: (2021)

Catatonic Schizophrenia: Cases with Possible Genetic Predisposition
por: Tariq, Maryam, et al.
Publicado: (2019)

Chronic Treatment With Aripiprazole Prevents Development of Dopamine Supersensitivity and Potentially Supersensitivity Psychosis
por: Tadokoro, Shigenori, et al.
Publicado: (2012)

Spontaneous Bladder Rupture in a Catatonic Schizophrenia Patient
por: Miyakoshi, Megumi, et al.
Publicado: (2023)

Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report
por: Håkansson, Anders, et al.
Publicado: (2015)

Reduction of Severity of Recurrent Psychotic Episode by Sustained Treatment with Aripiprazole in a Schizophrenic Patient with Dopamine Supersensitivity: A Case Report
por: Tadokoro, Shigenori, et al.
Publicado: (2017)

A case of Hallervorden-Spatz disease presenting as catatonic schizophrenia
por: Pawar, Yogesh, et al.
Publicado: (2013)

Circulating Neuroactive Steroid Levels in a Patient With Schizophrenia Who Showed Periodic Catatonia
por: Muneoka, Katsumasa, et al.
Publicado: (2023)

The catatonic dilemma expanded
por: Penland, Heath R, et al.
Publicado: (2006)

A Tale of Two Catatonic States
por: Birgi, Harleen Kaur, et al.
Publicado: (2023)

Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

Deaf-Mutism
Publicado: (1895)

Deaf-Mutism
Publicado: (1895)

On Deaf-Mutism
por: Purdon, Henry Samuel
Publicado: (1867)

Deaf-Mutism
Publicado: (1894)

Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia
por: Kanahara, Nobuhisa, et al.
Publicado: (2021)

Catatonic features in adolescents with schizophrenia with and without a comorbid pervasive developmental disorder
por: Waris, Petra, et al.
Publicado: (2014)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

DERMATOGLYPHICS IN FEMALE CATATONIC SCHIZOPHRENICS
por: Jhingan, H.P., et al.
Publicado: (1989)

DERMATOGLYPHICS IN MALE CATATONIC SCHIZOPHRENICS
por: Jhingan, H.P., et al.
Publicado: (1990)

On the problem of the catatonic disorders taxonomy
por: Lobanova, V., et al.
Publicado: (2022)

Case report: Evolution of catatonic mutism and psychotic symptoms in an adolescent with Down syndrome: transition from Down syndrome disintegrative disorder to anti-N-methyl-D-aspartate receptor encephalitis
por: Minamisawa, Yuki, et al.
Publicado: (2023)

Salivary Alpha-Amylase Activity Levels in Catatonic Schizophrenia Decrease after Electroconvulsive Therapy
por: Kanayama, Misako, et al.
Publicado: (2018)

Catatonic Schizophrenia Associated With Cerebrospinal GAD65 Autoantibodies: Case Report and Literature Review
por: Hansen, Niels, et al.
Publicado: (2022)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

Mutism. What to expect?
por: Santos Carrasco, I., et al.
Publicado: (2022)

Genetic association between G protein-coupled receptor kinase 6/β-arrestin 2 and dopamine supersensitivity psychosis in schizophrenia
por: Oda, Yasunori, et al.
Publicado: (2015)

CATATONIC SYNDROME : TREATMENT RESPONSE TO LORAZEPAM
por: Payee, Haniya, et al.
Publicado: (1999)

CATATONIC SYNDROME : TREATMENT RESPONSE TO LORAZEPAM
por: Patra, Alok, et al.
Publicado: (1999)

CATATONIC STUPOR AND TEMPORAL LOBE EPILEPSY
por: Dubin, Stephen E., et al.
Publicado: (1985)

(PO-051) Catatonic with COVID-19
por: Patel, Prit, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m9qhodq81b6cpnlgevm2ttegjt